source
- FDA approves Merck’s oral PCSK9 inhibitor Lipfendra, but cardiologists question its immediate impactThe FDA has granted approval to enlicitide, marketed by Merck as Lipfendra, marking the first oral PCSK9 inhibitor for lowering blood cholesterol. The drug arrives as new clinical guidelines encou…
- Arrowhead reports Phase 3 data showing potentially best-in-class triglyceride reduction, eyes FDA filingArrowhead Pharmaceuticals announced topline results from two late-stage Phase 3 trials (SHASTA-3 and SHASTA-4) of its siRNA drug plozasiran in patients with severe hypertriglyceridemia (sHTG). Th…